Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
The DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is some evidence that statins may have a protective and symptomatic benefit in Alzheimer disease (AD). The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild to moderate AD. METHODS: This was an international, multicenter, double-blind, randomized, parallel-group study. Subjects had mild to moderate probable AD (Mini-Mental State Examination score 13-25), were aged 50-90 years, and were taking donepezil 10 mg daily for > or 3 months prior to screening. Entry low-density lipoprotein cholesterol levels (LDL-C) were > 95 and < 195 mg/dL. Patients were randomized to atorvastatin 80 mg/day or placebo for 72 weeks followed by a double-blind, 8-week atorvastatin withdrawal phase. Coprimary endpoints were changes in cognition (Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog]) and global function (Alzheimer's Disease Cooperative Study Clinical Global Impression of Change [ADCS-CGIC]) at 72 weeks. RESULTS: A total of 640 patients were randomized in the study. There were no significant differences in the coprimary endpoints of ADAS-cog or ADCS-CGIC or the secondary endpoints. Atorvastatin was generally well-tolerated. CONCLUSIONS: In this large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks. This treatment was generally well-tolerated without unexpected adverse events. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that intensive lipid lowering with atorvastatin 80 mg/day in patients with mild to moderate probable Alzheimer disease (aged 50-90), taking donepezil, with low-density lipoprotein cholesterol levels between 95 and 195 mg/dL over 72 weeks does not benefit cognition (as measured by Alzheimer's Disease Assessment Scale-Cognitive Subscale) (p = 0.26) or global function (as measured by Alzheimer's Disease Cooperative Study Clinical Global Impression of Change) (p = 0.73) compared with placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies have suggested a beneficial effect of aspirin on cognition,465,466 although this was not confirmed in others.467,468”
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
A nonparametric method for automatic correction of intensity nonuniformity in MRI data
Sled, J. G., Zijdenbos, A. P., & Evans, A. C. (1998) · IEEE Transactions on Medical Imaging · doi:10.1109/42.668698 · Cited by 4,731
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationA new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Research works printed but not linked: 3
- Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:63–70.
- Austen B, Frears E, Davies H. Cholesterol upregulates production of A[beta] 1-40 and 1-42 in transfected cells. Neurobiol Aging 2000;21:254.
- Hoglund K, Wallin A, Blennow K. Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:87–92.
Cited by
Items 101–200 of 443
Satlin, A., Wang, J., Logovinsky, V., Berry, S., Swanson, C., Dhadda, S., & Berry, D. A. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.01.001 · Cited by 89
Effects of Statins on Memory, Cognition, and Brain Volume in the Elderly
Samaras, K., Makkar, S. R., Crawford, J. D., Kochan, N. A., Slavin, M. J., Wen, W., Trollor, J. N., Brodaty, H., & Sachdev, P. S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.09.041 · Cited by 87
Low levels of low-density lipoprotein cholesterol and cognitive decline
Hua, R., Ma, Y., Li, C., Zhong, B., & Xie, W. (2021) · Science Bulletin · doi:10.1016/j.scib.2021.02.018 · Cited by 87
Neuroinflammation, Microglia, and Cell-Association during Prion Disease
Carroll, J. A., & Chesebro, B. (2019) · Viruses · doi:10.3390/v11010065 · Cited by 82
Statins Use in Alzheimer Disease: Bane or Boon from Frantic Search and Narrative Review
Alsubaie, N., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alharbi, B., WAARD, M. M. D., Sabatier, J., Saad, H. M., & Batiha, G. E. (2022) · Brain Sciences · doi:10.3390/brainsci12101290 · Cited by 89
The Impact of Cholesterol, DHA, and Sphingolipids on Alzheimer’s Disease
Grimm, M. O. W., Zimmer, V. C., Lehmann, J., Grimm, H. S., & Hartmann, T. (2013) · BioMed Research International · doi:10.1155/2013/814390 · Cited by 80
Preventing Alzheimer's Disease by Targeting Vascular Risk Factors: Hope and Gap
Qiu, C. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120922 · Cited by 78
Jia, Q., Deng, Y., & Qing, H. (2014) · BioMed Research International · doi:10.1155/2014/837157 · Cited by 81
Barone, E., Di Domenico, F., & Butterfield, D. A. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.030 · Cited by 79
Lipid Lowering Agents, Cognitive Decline, and Dementia: The Three-City Study
Ancelin, M.-L., Carrière, I., Barberger-Gateau, P., Auriacombe, S., Rouaud, O., Fourlanos, S., Berr, C., Dupuy, A.-M., & Ritchie, K. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120064 · Cited by 78
Caselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
Initiative, T. A. D. N., Ueckert, S., Plan, E. L., Ito, K., Karlsson, M. O., Corrigan, B., & Hooker, A. C. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1315-5 · Cited by 81
Butterfield, D. A., Barone, E., & Mancuso, C. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.04.007 · Cited by 80
Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids
Torres, M., Parets, S., Fernández-Díaz, J., Beteta-Göbel, R., Rodríguez-Lorca, R., Román, R., Lladó, V., Rosselló, C. A., Fernández-García, P., & Escribá, P. V. (2021) · Membranes · doi:10.3390/membranes11120919 · Cited by 69
Padala, K. P., Padala, P. R., McNeilly, D. P., Geske, J., Sullivan, D. H., & POTTER, J. F. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2012.08.002 · Cited by 81
Cortese, G. P., & Bürger, C. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.08.027 · Cited by 86
Rabins, P. V., Rovner, B. W., Rummans, T., Schneider, L. S., & Tariot, P. N. (2017) · Focus · doi:10.1176/appi.focus.15106 · Cited by 72
Reitz, C. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110599 · Cited by 75
Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease
Kulshreshtha, A., & Piplani, P. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2625-7 · Cited by 87
Barone, E., Mancuso, C., Di Domenico, F., Sultana, R., Murphy, M. P., Head, E., & Butterfield, D. A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07538.x · Cited by 75
“Epidemiological studies suggest that statins use is associated with reduced risk of developing AD (Feldman et al. 2010).”
BackgroundAltered Cholesterol Homeostasis in Huntington’s Disease
Kacher, R., Mounier, C., Caboche, J., & Betuing, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.797220 · Cited by 70
Drug repurposing for Alzheimer’s disease and other neurodegenerative disorders
Cummings, J. L., Zhou, Y., Stone, A. V., Cammann, D., Tonegawa‐Kuji, R., Cacho, J. R. F., & Cheng, F. (2025) · Nature Communications · doi:10.1038/s41467-025-56690-4 · Cited by 88
Storck, S. E., & Pietrzik, C. U. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2267-3 · Cited by 79
Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions?
Ashrafian, H., Harling, L., Darzi, A. W., & Athanasiou, T. (2013) · Metabolic Brain Disease · doi:10.1007/s11011-013-9412-4 · Cited by 77
“Bariatric surgery”
ResultInsights into Computational Drug Repurposing for Neurodegenerative Disease
Paranjpe, M. D., Taubes, A., & Sirota, M. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.06.003 · Cited by 70
“This is exemplified by the fact that a newly-minted retrospective association that was found between increased statin use and reduced incidence of ADhas failed to be replicated in randomized controlled trials [88]– [90], demonstrating the inability of retrospective analyses to prove causation.”
BackgroundThe Role of P2X7 Receptor in Alzheimer’s Disease
Francistiová, L., Bianchi, C., Di Lauro, C., Sebastián-Serrano, Á., de Diego-García, L., Kobolák, J., Dinnyés, A., & Díaz-Hernández, M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00094 · Cited by 69
“Since some studies have shown increased levels of cholesterol promoting the production of Aβ, other clinical trials used statins likes hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors as cholesterol-lowering agents (Carlsson et al., 2008; Feldman et al., 2010).”
ResultSrivastava, S., & C. Haigis, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072526 · Cited by 70
“Also, clinical studies with statins have reported inconsistent and mixed results [33, 35, 36].”
ResultThe role of APP proteolytic processing in lipid metabolism
Grimm, M. O. W., Rothhaar, T. L., & Hartmann, T. (2011) · Experimental Brain Research · doi:10.1007/s00221-011-2975-6 · Cited by 76
Butterfield, D. A., Barone, E., Di Domenico, F., Cenini, G., Sultana, R., Murphy, M. P., Mancuso, C., & Head, E. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001118 · Cited by 67
Pleiotropic effects of statins on brain cells
Sodero, A. O., & Barrantes, F. J. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183340 · Cited by 73
Alzheimer’s Disease, Cholesterol, and Statins: The Junctions of Important Metabolic Pathways
Silva, T., Teixeira, J., Remião, F., & Borges, F. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201204964 · Cited by 65
Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways
Yu, L., Wang, M., Yang, Y., Xu, F., Zhang, X., Xie, F., Gao, L., & Li, X. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008696 · Cited by 74
Statin use and dementia risk: A systematic review and updated meta‐analysis
Westphal Filho, F. L., Moss Lopes, P. R., Menegaz de Almeida, A., Sano, V. K. T., Tamashiro, F. M., Gonçalves, O. R., de Moraes, F. C. A., Kreuz, M., Kelly, F. A., & Silveira Feitoza, P. V. (2025) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.70039 · Cited by 62
Broadstock, M., Ballard, C., & Corbett, A. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.936848 · Cited by 58
Intensive LDL-cholesterol lowering therapy and neurocognitive function
Banach, M., Rizzo, M., Nikolić, D., Howard, G., Howard, V. J., & Mikhailidis (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.001 · Cited by 68
Petek, B., Häbel, H., Xu, H., Villa-Lopez, M., Kalar, I., Hoang, M. T., Maioli, S., Pereira, J. B., Mostafaei, S., Winblad, B., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01360-0 · Cited by 65
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Leduc, V, De Beaumont, L., Théroux, L., Dea, D., Aisen, P., Petersen, R. C., Initiative, T. A. D. N., Dufour, R., & Poirier, J. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.81 · Cited by 63
“However, results of prospective studies have been inconsistent (54–56), and recent double blind placebo-controlled clinical trials in mild-to-moderate AD using simvastatin and atorvastatin for at least 6 months failed to show disease stabilization or improvement (57, 58), mostly due to a marked treatment response hete…”
ResultMartínková, J., Quevenco, F., Karcher, H., Ferrari, A., Sandset, E. C., Szoeke, C. E. I., Hort, J., Schmidt, R., Chadha, A. S., & Ferretti, M. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24124 · Cited by 68
2015 Korean Guidelines for Management of Dyslipidemia
Committee for Guidelines for Management of Dyslipidemia (2015) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2015.4.1.61 · Cited by 72
Swiger, K. J., & Martin, S. S. (2015) · Drug Safety · doi:10.1007/s40264-015-0296-6 · Cited by 67
Cochrane review on ‘Statins for the treatment of dementia’
McGuinness, B., O'Hare, J., Craig, D., Bullock, R., Malouf, R., & Passmore, P. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3797 · Cited by 64
“, 2005), Atorvastatin/Donepezil in Alzheimer’s Disease (LEADe) study 2010 (Feldman et al., 2010) and Simons et al.”
BackgroundSato, N., & Morishita, R. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00064 · Cited by 66
“However, a randomized controlled study failed to show beneficial effects on the cognitive decline in AD (Feldman et al., 2010).”
BackgroundCan We Treat Neuroinflammation in Alzheimer’s Disease?
Sánchez‐Sarasúa, S., Fernández-Pérez, I., Espinosa‐Fernández, V., Sánchez‐Pérez, A. M., & Ledesma, J. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228751 · Cited by 67
“[66] 2010 = ADCS-CGIC score ↓ Total cholesterol levels”
BackgroundImaging endpoints for clinical trials in Alzheimer’s disease
Cash, D. M., Rohrer, J. D., Ryan, N. S., Ourselin, S., & Fox, N. C. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0087-9 · Cited by 62
Ahmed, H., Wang, Y., Griffiths, W. J., Levey, A. I., Pikuleva, I., Liang, S. H., & Haider, A. (2024) · Brain · doi:10.1093/brain/awae028 · Cited by 56
Kosowski, M., Smolarczyk, J., Hachuła, M., Maligłówka, M., Basiak, M., Machnik, G., Pudło, R., & Okopień, B. (2021) · Molecules · doi:10.3390/molecules26102838 · Cited by 66
Shinohara, M., Sato, N., Shimamura, M., Kurinami, H., Hamasaki, T., Chatterjee, A., Rakugi, H., & Morishita, R. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00071 · Cited by 59
“Two recent randomized clinical studies enrolling around 400 mild-to-moderate AD patients have failed to show benefits of atorvastatin and simvastatin on cognitive function (Feldman et al., 2010; Sano et al., 2011).”
BackgroundPicard, C., Poirier, A., Bélanger, S., Labonté, A., Auld, D., Poirier, J., & on behalf of the PREVENT-AD Research Group (2019) · PLOS ONE · doi:10.1371/journal.pone.0220254 · Cited by 59
Cholesterol, Statins, and Dementia: What the Cardiologist Should Know
Wanamaker, B. L., Swiger, K. J., Blumenthal, R. S., & Martin, S. S. (2015) · Clinical Cardiology · doi:10.1002/clc.22361 · Cited by 58
High Hemoglobin A1c and Diabetes Predict Memory Decline in the Health and Retirement Study
Marden, J. R., Mayeda, E. R., Tchetgen, E. J. T., Kawachi, I. I., & Glymour, M. M. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000182 · Cited by 64
Serrano‐Pozo, A., Aldridge, G. M., & Zhang, Q. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170184 · Cited by 64
Clinical trials for preventing post stroke cognitive impairment
Ankolekar, S., Geeganage, C. M., Anderton, P., Hogg, C., & Bath, P. M. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.08.052 · Cited by 62
New and emerging treatments for Alzheimer’s disease
Corbett, A., Smith, J., & Ballard, C. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.43 · Cited by 56
Statin therapy: does sex matter?
Faubion, S. S., Kapoor, E., Moyer, A. M., Hodis, H. N., & Miller, V. M. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001412 · Cited by 61
“Although the study included about 50% women, the data were not disaggregated by sex.(58) The negative outcomes of this study may relate to the stage of disease at the time of initiation of therapy, type of statin, dose, and duration of therapy.”
ResultValenti, R., Pantoni, L., & Markus, H. S. (2014) · BMC Medicine · doi:10.1186/s12916-014-0160-z · Cited by 51
Therapeutic targets of brain insulin resistance in sporadic Alzheimer s disease
Monte, S. M. D. L. (2012) · Frontiers in Bioscience · doi:10.2741/e482 · Cited by 58
Statins and Cognitive Decline in Older Adults with Normal Cognition or Mild Cognitive Impairment
Steenland, K., Zhao, L., Goldstein, F. C., & Levey, A. I. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12414 · Cited by 56
Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease
Chase, T. N., Farlow, M. R., & Clarence-Smith, K. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0511-x · Cited by 52
Cheng, Y., Chiu, M., Chen, Y., Cheng, T., Lai, Y., & Chen, T. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00658-7 · Cited by 63
Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before
Mancuso, C., Siciliano, R., Barone, E., Butterfield, D. A., & Preziosi, P. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.601740 · Cited by 60
“The results of the LEADe RCT showed a non-significant effect of donepezil plus atorvastatin on both cognition and global function [91].”
ResultApolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease
Kline, A. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt135 · Cited by 48
Cholesterol and Alzheimer's disease: A still poorly understood correlation
Ricciarelli, R., Canepa, E., Marengo, B., Marinari, U. M., Poli, G., Pronzato, M. A., & Domenicotti, C. (2012) · IUBMB Life · doi:10.1002/iub.1091 · Cited by 49
Rahimi, K., Majoni, W., Merhi, A., & Emberson, J. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs005 · Cited by 55
Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease
de la Monte, S. (2012) · Frontiers in Bioscience · doi:10.2741/482 · Cited by 49
Pitavastatin decreases tau levels via the inactivation of Rho/ROCK
Hamano, T., Yen, S.-H., Gendron, T., Ko, L.-W., & Kuriyama, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.020 · Cited by 49
Kurata, T., Miyazaki, K., Kozuki, M., Morimoto, N., Ohta, Y., Ikeda, Y., & Abe, K. (2012) · Neurological Research · doi:10.1179/1743132812y.0000000054 · Cited by 49
Fernández-de-Retana, S., Cano-Sarabia, M., Marazuela, P., Sánchez-Quesada, J. L., Garcia-Leon, A., Montañola, A., Montaner, J., Maspoch, D., & Hernández-Guillamon, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15215-w · Cited by 49
Association Between Statin Use and Risk of Dementia After a Concussion
Redelmeier, D. A., Manzoor, F., & Thiruchelvam, D. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1148 · Cited by 48
Stuart, S. A., Robertson, J. D., Marrion, N. V., & Robinson, E. S. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075467 · Cited by 50
Schilling, J. M., Cui, W., Godoy, J. C., Risbrough, V. B., Niesman, I. R., Roth, D. M., Patel, P. M., Drummond, J. C., Patel, H. H., Zemljic‐Harpf, A. E., et al. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.03.014 · Cited by 48
Petek, B., Villa‐Lopez, M., Loera‐Valencia, R., Gereñu, G., Winblad, B. G., Kramberger, M. G., Ismail, M. A. M., Eriksdotter, M., & Ptacek, S. G. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12838 · Cited by 50
Kerola, T. V., Kettunen, R., & Nieminen, T. V. M. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.10.018 · Cited by 52
“atorvastatin was used for 72 weeks in mild-to-moderate AD patients without any significant benefit in cognitive measures [92].”
MethodXuan, K., Zhao, T., Qu, G., Liu, H., Chen, X., & Sun, Y. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04243-6 · Cited by 50
Alzheimer’s Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review
Knorz, A. L., & Quante, A. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211044746 · Cited by 50
Risk of neuropsychiatric adverse effects of lipid-lowering drugs: a mendelian randomization study
Alghamdi, J., Matou-Nasri, S., Alghamdi, F., Alghamdi, S., Alfadhel, M., & Padmanabhan, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy060 · Cited by 44
Grimm, M., Regner, L., Mett, J., Stahlmann, C., Schorr, P., Nelke, C., Streidenberger, O., Stoetzel, H., Winkler, J., Zaidan, S., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111809 · Cited by 44
Kurata, T., Miyazaki, K., Morimoto, N., Kawai, H., Ohta, Y., Ikeda, Y., & Abe, K. (2013) · Neurological Research · doi:10.1179/1743132812y.0000000127 · Cited by 46
Statins and the brain: New perspective for old drugs
Ling, Q., & Tejada-Simon, M. V. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.013 · Cited by 43
Statins: The Role in the Treatment and Prevention of Alzheimer's Neurodegeneration
Pac-Soo, C., Lloyd, D. G., Vizcaychipi, M. P., & Ma, D. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110524 · Cited by 46
Considering a new paradigm for Alzheimer's disease research
Langley, G. R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.013 · Cited by 43
“[90,91]”
Statins for primary prevention of venous thromboembolism
Li, L., Zhang, P., Tian, J. H., & Yang, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008203.pub3 · Cited by 40
Zanchetti, A., Liu, L., Mancia, G., Parati, G., Grassi, G. M., Stramba‐Badiale, M., Silani, V., Bilo, G., Corrao, G., Zambon, A., et al. (2014) · Journal of Hypertension · doi:10.1097/hjh.0000000000000253 · Cited by 40
Wu, C. ‐., Yang, Y. ‐., Lin, T. ‐., Tsai, C. ‐., Hwang, J. ‐., Lin, J. ‐., Chen, P. ‐., Chiang, F. ‐., & Lin, L. ‐. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12262 · Cited by 39
Cognitive Effects of Statin Medications
Kelley, B. J., & Glasser, S. P. (2014) · CNS Drugs · doi:10.1007/s40263-014-0147-5 · Cited by 42
Bullain, S., & Doody, R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15023 · Cited by 38
“…itself, regardless of the approach, may also limit our ability to detect clinical efficacy; intervention durations even > 1 year (Aisen et al., 2008; Feldman et al., 2010; Sano et al., 2011; Van Gool et al., 2001) may not provide an adequate exposure time to result in a measurable clinical benefit.”
InfluentialSelf-citationInflammation as a Possible Link Between Dyslipidemia and Alzheimer’s Disease
Oliveira, B. C. D. L., Bellozi, P. M. Q., Reis, H. J., & de Oliveira, A. C. P. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.012 · Cited by 44
Alzheimer's disease: Cholesterol a menace?
Mathew, A., Yoshida, Y., Maekawa, T., & Kumar, D. S. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.06.006 · Cited by 44
Lesser, G. T., Beeri, M. S., Schmeidler, J., Purohit, D. P., & Haroutunian, V. (2011) · Current Alzheimer Research · doi:10.2174/156720511795563755 · Cited by 39
Glodzik, L., Rusinek, H., Kamer, A. R., Pirraglia, E., Tsui, W., Mosconi, L., Li, Y., McHugh, P. F., Murray, J., Williams, S., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.02.007 · Cited by 42
Lipid lowering for prevention of venous thromboembolism: a network meta-analysis
Farmakis, I. T., Christodoulou, K. C., Hobohm, L., Konstantinides, S., & Valerio, L. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae361 · Cited by 38
Candeias, E., Duarte, A. I., Sebastião, I., Fernandes, M. A. S., Plácido, A. I., Carvalho, C., Correia, S. C., Santos, R. X., Seiça, R. M. F., Santos, M. S., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0155-1 · Cited by 41
Chen, J.-M., Chang, C.-W., Chang, T.-H., Hsu, C.-C., Horng, J.-T., & Sheu, W. H.-H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088434 · Cited by 35
Geldmacher, D., & Kerwin, D. R. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12r01474 · Cited by 44
MAM and C99, key players in the pathogenesis of Alzheimer’s disease
Pera, M., Montesinos, J., Larrea, D., Agrawal, R. R., VELASCO, K. R., Stavrovskaya, I. G., Yun, T. D., & Área-Gómez, E. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.016 · Cited by 37
Improving Alzheimer's disease phase II clinical trials
Greenberg, B., Carrillo, M. C., Ryan, J. M., Gold, M., Gallagher, K., Grundman, M., Berman, R., Ashwood, T., & Siemers, E. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.02.002 · Cited by 37
Risk Profiles of Alzheimer Disease
Bilbul, M., & Schipper, H. M. (2011) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100012129 · Cited by 40
Arbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 34
Remembering Statins: Do Statins Have Adverse Cognitive Effects?
Bitzur, R. (2016) · Diabetes Care · doi:10.2337/dcs15-3022 · Cited by 33
Isoprenoids and tau pathology in sporadic Alzheimer's disease
Pelleïeux, S., Picard, C., Lamarre-Théroux, L., Dea, D., Leduc, V., Tsantrizos, Y. S., & Poirier, J. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.01.012 · Cited by 32
Metadata
- Authors
- Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., & Breazna, A.
- Affiliations
- San Francisco General Hospital (US)
- From the Division of Neurology (H.H.F.), University of British Columbia, UBCH Clinic for Alzheimer's Disease and Related Disorders, Vancouver, Canada; Department of Neurology (R.S.D.), Baylor College of Medicine, Houston, TX; Aging Research Center (M.K.), Karolinska Institutet, Stockholm, Sweden; Ralph & Muriel Roberts Laboratory For Neurodegenerative Research (D.L.S.), Sun Health Research Institute, Sun City, AZ; San Francisco General Hospital (D.D.W.), San Francisco, CA; RICE (The Research...
- Venue
- Neurology
- Published
- 2010-03-23
- Volume
- 74
- Issue
- 12
- Pages
- 956-964
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2030025114
- Cited by
- 438
- References
- 38
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 14 · 2023: 12 · 2022: 10 · 2021: 18 · 2020: 27 · 2019: 42 · 2018: 16 · 2017: 26 · 2016: 34 · 2015: 26 · 2014: 33 · 2013: 28 · 2012: 49
- FWCI
- 32.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Pfizer
- IXICO
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- atorvastatin, Alzheimer's disease, statins, lipid lowering, donepezil, cognitive function, global function, LDL cholesterol, drug safety and efficacy
- MeSH terms
- Atorvastatin, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Heptanoic Acids, Hippocampus, Humans, Cholesterol, LDL, Magnetic Resonance Imaging, Male, Middle Aged, Organ Size, Pyrroles, Cholinergic Antagonists, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.